Teva’s Ascent Faces Mounting Skepticism

Pharmaceutical giant Teva is experiencing a remarkable surge in its share price, yet a growing chorus of doubters is emerging just as the stock approaches record levels. While recent regulatory approvals in Europe are fueling the growth narrative, a notable increase in short-selling activity is signaling underlying market concerns.

Legal Setback and Clinical Progress in the US

The company’s trajectory recently encountered a hurdle in the United States. A federal court dismissed Teva’s lawsuit challenging the Medicare drug price negotiation program. The company had contended that the initiative infringed upon its property rights for medications such as Austedo.

Offsetting this legal development, positive research data has emerged. The IMPACT-TD study confirmed the efficacy of Austedo for treating Tardive Dyskinesia. Patient reports indicated a reduction in involuntary movements and an associated improvement in quality of life.

European Expansion with Biosimilars

A significant strategic achievement was unlocked in Europe. The European Commission granted marketing authorization for two biosimilar candidates, Ponlimsi and Degevma. These products are equivalents to the blockbuster drugs Prolia and Xgeva, clearing the way for their imminent launch across European markets. These approvals represent a critical milestone for Teva’s “Pivot to Growth” strategy, substantially strengthening its specialized medicines portfolio.

The planned market introductions in the coming months are expected to deliver fresh revenue streams for both its generic and specialized business segments. At a time of mounting cost pressures in global healthcare systems, these more affordable alternatives to originator drugs could provide Teva with a distinct competitive advantage.

Should investors sell immediately? Or is it worth buying Teva?

Record Highs Amidst Rising Short Interest

Equity in Teva is trading near its 52-week peak, having advanced more than 40 percent over the past twelve months. This powerful rally reflects robust investor confidence in the company’s ongoing strategic transformation. However, this optimism is tempered by a concerning trend: short interest has climbed by over 6 percent recently.

Currently, more than 50 million shares have been sold short, accounting for 4.4 percent of the company’s float. This places Teva notably above the industry average of 3.5 percent for short interest. Skeptical investors would require nearly six days to cover their positions should the share price continue its upward trend.

Pivotal Investor Meetings Loom

The sustainability of the current rally will face a key test in December. Teva’s executive team is scheduled to present at three major investor conferences. These appearances present a crucial opportunity to reinforce the credibility of its growth strategy and win over cautious market participants.

The central question remains: Will the momentum from the European biosimilar launches be sufficient to force a retreat by the growing cohort of short sellers? The outcome of these December events could very well set the directional tone for the stock heading into 2026.